Literature DB >> 23296510

The Twin Epidemics of Tuberculosis and HIV.

George M Varghese1, Jeshina Janardhanan, Ravikar Ralph, Ooriapadickal C Abraham.   

Abstract

The deadly combination of tuberculosis (TB) and human immunodeficiency virus (HIV) currently ravaging the world, taking a toll of about 0.35 million people every year, is one of the major public health crises of the decade. Throughout the course of HIV infection, the risk of acquisition, reactivation, and reinfection of TB keeps increasing substantially as the immune deficiency progresses. TB coinfected patients inadvertently facilitate HIV infection by release of the proinflammatory cytokines and overexpression of coreceptors CXCR4 and CCR5; thereby, the progression of each is facilitated. The difficulties in diagnosing active tuberculosis in HIV-infected individuals poses a great challenge that is further complicated by the challenges in identification of latent TB infection, creating a setback to preventive therapy. Furthermore, prescribing antituberculous therapy and antiretroviral therapy together poses several management challenges, including drug interactions, added toxicities, and TB immune reconstitution inflammatory syndrome. The current approach to diagnosis, prevention, and treatment strategies in TB and HIV coinfected individuals, along with epidemiology and overview of pathogenetic interplay of both microbes, is reviewed here.

Entities:  

Year:  2013        PMID: 23296510     DOI: 10.1007/s11908-012-0311-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  63 in total

1.  A nested case-control study on treatment-related risk factors for early relapse of tuberculosis.

Authors:  Kwok C Chang; Chi C Leung; Wing W Yew; Suzanne C Ho; Cheuk M Tam
Journal:  Am J Respir Crit Care Med       Date:  2004-09-16       Impact factor: 21.405

2.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

3.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew Gray; Tanuja Gengiah; Gonasagrie Nair; Sheila Bamber; Aarthi Singh; Munira Khan; Jacqueline Pienaar; Wafaa El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

5.  Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.

Authors:  Stephen D Lawn; Landon Myer; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

6.  Impact of HIV infection on the recurrence of tuberculosis in South India.

Authors:  Sujatha Narayanan; Soumya Swaminathan; Philip Supply; Sivakumar Shanmugam; Gopalan Narendran; Lalitha Hari; Ranjani Ramachandran; Camille Locht; Mohideen Shaheed Jawahar; Paranji Raman Narayanan
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

7.  Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.

Authors:  Diane V Havlir; Haileyesus Getahun; Ian Sanne; Paul Nunn
Journal:  JAMA       Date:  2008-07-23       Impact factor: 56.272

8.  Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Authors:  Stephen D Lawn; Landon Myer; David Edwards; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

Review 9.  Recent developments in treatment of latent tuberculosis infection.

Authors:  Dick Menzies; Hamdan Al Jahdali; Badriah Al Otaibi
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

Review 10.  Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.

Authors:  Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich
Journal:  PLoS Med       Date:  2012-07-24       Impact factor: 11.069

View more
  4 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.

Authors:  C G Le Prell; C Ojano-Dirain; E W Rudnick; M A Nelson; S J DeRemer; D M Prieskorn; J M Miller
Journal:  J Assoc Res Otolaryngol       Date:  2014-03-04

3.  Tuberculosis Elimination Efforts in the United States in the Era of Insurance Expansion and the Affordable Care Act.

Authors:  Victor Balaban; Suzanne M Marks; Sue C Etkind; Dolly J Katz; Julie Higashi; Jennifer Flood; Ann Cronin; Christine S Ho; Awal Khan; Terence Chorba
Journal:  Public Health Rep       Date:  2015 Jul-Aug       Impact factor: 2.792

4.  Tuberculosis, human immunodeficiency virus, and the immune reconstitution inflammatory syndrome.

Authors:  A Rapose; S Karande
Journal:  J Postgrad Med       Date:  2017 Oct-Dec       Impact factor: 1.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.